Informed Consent and Adverse events [GxP / QC / QA]

posted by yogesh1004 – India, 2012-10-09 08:36 (4996 d 11:18 ago) – Posting: # 9345
Views: 6,853

Dear All,

When a Informed consent is designed for single dose two way crossover BABE study, is it necessary to document all the adverse events described in the label?

As the label will have the adverse events observed in the clinical studies (in patients, adverse events observed in combination studies and also the adverse events observed in multiple dose studies.

Is it is also necessary to document the adverse events reported for that molecule as mentioned in the label in Protocol and Informed consent form?

Or is it is sufficient to write the adverse events observed with out the study details and percentages.

recently FDA issued an 483 in this aspect to one of the CRO.

Please guide me in this regard.

Regards,

S.Yogesh


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
122 visitors (0 registered, 122 guests [including 17 identified bots]).
Forum time: 19:54 CEST (Europe/Vienna)

I have never in my life learned anything
from any man who agreed with me.    Dudley Field Malone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5